Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743380 | 0.91 | LIPE (0.54) | LIPEEGLN1RORCKCNJ1CYP3A4 | |
| SCHEMBL745778 | 0.83 | LIPE (0.61) | LIPE | |
| SCHEMBL745718 | 0.80 | CYP2C9 (0.46) | CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL745622 | 0.80 | LIPE (0.69) | LIPEEGLN1 | |
| SCHEMBL743652 | 0.79 | LIPE (0.53) | LIPEEGLN1RORC | |
| SCHEMBL743640 | 0.79 | LIPE (0.79) | LIPE | |
| SCHEMBL14238794 | 0.78 | ALDH1A1 (0.37) | RORCCYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL3744657 | 0.77 | LIPE (0.58) | LIPEEGLN1TSHR | |
| SCHEMBL746972 | 0.76 | LIPE (0.67) | LIPEEGLN1KCNJ1 | |
| SCHEMBL10034 | 0.76 | EGLN1 (0.46) | LIPEEGLN1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | claimed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | claimed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | claimed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-9593202-B2 | Polycarbonate resin composition pellets and process for manufacturing same | IDEMITSU KOSAN CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20140364546-A1 | POLYCARBONATE RESIN COMPOSITION PELLETS AND PROCESS FOR MANUFACTURING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-7816424-B2 | Biodegradable plastics composition, molded article of the composition, and method of controlling biodegradation rate | NISSHINBO INDUSTRIES, INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20070265371-A1 | BIODEGRADABLE PLASTICS COMPOSITION, MOLDED ARTICLE OF THE COMPOSITION, AND METHOD OF CONTROLLING BIODEGRADATION RATE | NISSHINBO INDUSTRIES, INC. (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | LIPE 10/4885EGLN1 2307/4885RORC 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.